Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.39 |
| ▸ | MET | P08581 | 16/20 | 0.37 |
| ▸ | AXL | P30530 | 12/20 | 0.36 |
| ▸ | MERTK | Q12866 | 12/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 8/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104399 | 0.89 | MET (0.40) | METAXLMERTKTYRO3KDR | |
| SCHEMBL3107510 | 0.86 | MET (0.41) | METAXLMERTKTYRO3KDR | |
| SCHEMBL3112020 | 0.84 | MET (0.36) | METAXLMERTKTYRO3KDR | |
| SCHEMBL3112723 | 0.84 | AXL (0.37) | METAXLMERTKTYRO3KDR | |
| SCHEMBL3114517 | 0.83 | AXL (0.40) | METAXLMERTKTYRO3KDR | |
| SCHEMBL3101845 | 0.83 | MET (0.42) | METAXLMERTKTYRO3KDR | |
| SCHEMBL3107657 | 0.83 | AXL (0.39) | METAXLMERTKTYRO3 | |
| SCHEMBL3101351 | 0.83 | MAPK1 (0.38) | METAXLMERTKTYRO3 | |
| SCHEMBL13101869 | 0.82 | MET (0.54) | METAXLMERTKKDRRET | |
| SCHEMBL2280464 | 0.82 | MET (0.45) | METAXLMERTKKDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | claimed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | LRRK2 914/4885MET 357/4885AXL 117/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | LRRK2 914/4885MET 357/4885AXL 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.